Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 21, Issue 7, Pages 1155-1166Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2015.03.002
Keywords
Multiple myeloma; Transplantation; Recommendations; Guidelines
Categories
Funding
- Celgene
- Onyx
- Millenium/Takeda
- Sanofi
- Celegene
- Janssen
- Millenium
- Otsuka
- Celegne
Ask authors/readers for more resources
Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered in the context of this evolution. In this evidence-based review, we have critically analyzed the data from the most recent clinical trials to better understand how to incorporate HCT and when HCT is indicated. We have provided our recommendations based on Strength of evidence with the knowledge that ongoing clinical trials make this a dynamic field. Within this document, we discuss the decision to proceed with autologous HCT, factors to consider before proceeding to HCT, the role of tandem autologous HCT, post-HCT maintenance therapy, and the role of allogeneic HCT for patients with MM. (C) 2015 American Society for Blood and Marrow Transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available